Teduglutide in Short Bowel Syndrome Patients

Medical University of Vienna17 enrolled

Overview

A retrospective analysis was performed using data of patients suffering from non-malignant SBS-IF. They were treated with teduglutide in a multidisciplinary SBS-IF program at a single university medical center between June 2016 and June 2020.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Short Bowel Syndrome

Interventions

TeduglutideDRUG

effect of teduglutide on intestinal rehabilitation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * SBS-IF Exclusion Criteria: * \< 18 years * Incompliance * \< 6 months of treatment

Outcomes

Primary Outcomes

enteral autonomy

percentage of patients reaching complete discontinuation of parenteral support

Time frame: at least 6 months of teduglutide treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.